胃癌组织中EGFR,C-erbB-2蛋白的表达及其临床价值  

Expression of EGFR and C-erbB-2 protein in gastric cancer and their clinical values

作　　者：陈斌[1] 丁轶[2] 罗荣城[1] 

机构地区：[1]南方医科大学南方医院肿瘤中心,广州510515 [2]南方医科大学南方医院放疗科,广州510515

出　　处：《广东医学》2007年第10期1608-1610,共3页Guangdong Medical Journal

基　　金：广东省自然科学基金重点项目(编号:2004037050)

摘　　要：目的研究胃癌组织中EGFR,C-erbB-2蛋白的表达与临床病理特征及生存期的关系,探讨其成为胃癌预后指标和分子靶点的可行性。方法应用免疫组织化学方法检测具有随访资料的103例胃癌标本中EGFR,C-erbB-2蛋白的表达,并将检测结果与临床病理特征进行综合分析。结果①103例胃癌组织中EG-FR,C-erbB-2蛋白的阳性表达率分别为42.7%(44/103),31.1%(32/103),在胃正常组织中均无表达;②EG-FR,C-erbB-2蛋白表达与患者的性别、年龄、肿瘤大小、部位、分化程度均无相关性(P>0.05),而与肿瘤的浸润深度、病理分期、淋巴结转移、远处转移相关(P<0.05);③EGFR,C-erbB-2蛋白表达阳性患者中位生存时间分别为11.0,10.1个月,表达阴性患者中位生存时间分别为65.2,64.5个月,EGFR,C-erbB-2表达阳性患者与阴性患者生存时间差异有显著性(P<0.05);④EGFR与C-erbB-2蛋白联合表达与生存期相关(PEGFR=0.027,Pc-erB-2=0.000,RREGFR=1.965,RRc-erB-2=3.153),二者的阳性表达有降低胃癌患者生存时间的危险,C-erbB-2阳性表达的相对危险度较大。结论①EGFR,C-erbB-2蛋白在胃癌组织中的阳性表达率较高,为IMC-C225,Herceptin等分子靶向治疗药物在胃癌的应用提供了理论依据;②测定EGFR,C-erbB-2蛋白的表达,对临床判断患者预后及指导治疗有较大帮助;③EGFR与C-erbB-2联合表达对胃癌的进展可能协同作用。Objective To investigate the expression of EGFR, C - erbB - 2 in gastric cancer and their relationship with clinical pathologic character and survival, and to discuss the feasibility of EGFR, C - erbB - 2 as prognostic markers and molecular target. Methods The expression of EGFR, C - erbB - 2 in gastric cancer was studied by immuno- histochemical technique and was correlated with follow -up data and clinical pathologic character. Results ①The 44 of 103 gastric cancer specimens （42.7%） were positive for EGFR. Thirty -two of 103 gastric cancer specimens （31.1%） were positive for C - erbB - 2 and the expression of EGFR and C - erbB - 2 was not found in gastric normal tissue ; ②Their expression was not correlated with sex, age, size and site of tumor and degree of differentiation （ P 〉 0.05 ）. The positive expression rates of EGFR and C - erbB - 2 were correlated with depth of invasion, clinical stage, lymph node and distant metastasis and survival of gastric cancer patients （ P 〈 0. 05 ） ; ③Median survival of patients with E positive GFR and C - erbB- 2 was 11.0 and 10. 1 months, respectively. Median survival of patients with negative EGFR and C -erbB -2 was 65.2 and 64. 5 month, respectively. There was significant difference between median survival of patients with positive and negative EGFR（ P 〈 0.05 ） ;（4）EGFR expression combined with C -erbB -2 expression was correlated with survival（ PEGFR =0. 027, Pc-erB-2 = 0. 000, RREGFR = 1. 965, RRc-erB-2 = 3.153 ）. Their expression may decrease survival of patients with gastric cancer, especially C - erbB - 2 expression. Conclusion①High positive rate of EGFR and C - erbB - 2 expression in gastric cancer provides a theoretical basis for application of molecular targeted drugs, such as IMC - C225 and Herceptin; ②Determination of the expression of EGFR and C - erbB - 2 can help to predict the prognosis and guide treatment; ③ EGFR combined with C -erbB -2 expression may have synergistic effect on gastric cancer progression.

关 键 词：胃肿瘤EGFR C-ERBB-2 生存期 分子靶点 

分 类 号：R737.9[医药卫生—肿瘤]